1
|
Najjari Z, Sadri F, Varshosaz J. Smart stimuli-responsive drug delivery systems in spotlight of COVID-19. Asian J Pharm Sci 2023; 18:100873. [PMID: 38173712 PMCID: PMC10762358 DOI: 10.1016/j.ajps.2023.100873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 08/15/2023] [Accepted: 10/11/2023] [Indexed: 01/05/2024] Open
Abstract
The world has been dealing with a novel severe acute respiratory syndrome (SARS-CoV-2) since the end of 2019, which threatens the lives of many people worldwide. COVID-19 causes respiratory infection with different symptoms, from sneezing and coughing to pneumonia and sometimes gastric symptoms. Researchers worldwide are actively developing novel drug delivery systems (DDSs), such as stimuli-responsive DDSs. The ability of these carriers to respond to external/internal and even multiple stimuli is essential in creating "smart" DDS that can effectively control dosage, sustained release, individual variations, and targeted delivery. To conduct a comprehensive literature survey for this article, the terms "Stimuli-responsive", "COVID-19″ and "Drug delivery" were searched on databases/search engines like "Google Scholar", "NCBI", "PubMed", and "Science Direct". Many different types of DDSs have been proposed, including those responsive to various exogenous (light, heat, ultrasound and magnetic field) or endogenous (microenvironmental changes in pH, ROS and enzymes) stimuli. Despite significant progress in DDS research, several challenging issues must be addressed to fill the gaps in the literature. Therefore, this study reviews the drug release mechanisms and applications of endogenous/exogenous stimuli-responsive DDSs while also exploring their potential with respect to COVID-19.
Collapse
Affiliation(s)
- Zeinab Najjari
- Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Farzaneh Sadri
- Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Jaleh Varshosaz
- Novel Drug Delivery Systems Research Center, Department of Pharmaceutics, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
2
|
Zhao Y, Shirasu T, Yodsanit N, Kent E, Ye M, Wang Y, Xie R, Gregg AC, Huang Y, Kent KC, Guo LW, Gong S, Wang B. Biomimetic, ROS-detonable nanoclusters - A multimodal nanoplatform for anti-restenotic therapy. J Control Release 2021; 338:295-306. [PMID: 34416322 DOI: 10.1016/j.jconrel.2021.08.025] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 07/14/2021] [Accepted: 08/15/2021] [Indexed: 12/18/2022]
Abstract
The long-term success of endovascular intervention has long been overshadowed by vessel re-occlusion, also known as restenosis. Mainstream anti-restenotic devices, such as drug-eluting stent (DES) and drug-coated balloon (DCB), were recently shown with suboptimal performances and life-threatening complications, thereby underpinning the urgent need for alternative strategies with enhanced efficacy and safety profile. In our current study, we engineered a multimodal nanocluster formed by self-assembly of unimolecular nanoparticles and surface coated with platelet membrane, specifically tailored for precision drug delivery in endovascular applications. More specifically, it incorporates the combined merits of platelet membrane coating (lesion targetability and biocompatibility), reactive oxygen species (ROS)-detonable "cluster-bomb" chemistry (to trigger the large-to-small size transition at the target site, thereby achieving longer circulation time and higher tissue penetration), and sustained drug release. Using RVX-208 (an emerging anti-restenotic drug under clinical trials) as the model payload, we demonstrated the superior performances of our nanocluster over conventional poly(lactic-co-glycolic acid) (PLGA) nanoparticle. In cultured vascular smooth muscle cell (VSMC), the drug-loaded nanocluster induced effective inhibition of proliferation and protective gene expression (e.g., APOA-I) with a significantly reduced dosage of RVX-208 (1 μM). In a rat model of balloon angioplasty, intravenous injection of Cy5.5-tagged nanocluster led to greater lesion targetability, improved biodistribution, and deeper penetration into injured vessel walls featuring enriched ROS. Moreover, in contrast to either free drug solution or drug-loaded PLGA nanoparticle formulation, a single injection with the drug-loaded nanocluster (10 mg/kg of RVX-208) was sufficient to substantially mitigate restenosis. Additionally, this nanocluster also demonstrated biocompatibility according to in vitro cytotoxicity assay and in vivo histological and tissue qPCR analysis. Overall, our multimodal nanocluster offers improved targetability, tissue penetration, and ROS-responsive release over conventional nanoparticles, therefore making it a highly promising platform for development of next-generation endovascular therapies.
Collapse
Affiliation(s)
- Yi Zhao
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
| | - Takuro Shirasu
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
| | - Nisakorn Yodsanit
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
| | - Eric Kent
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
| | - Mingzhou Ye
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
| | - Yuyuan Wang
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA
| | - Ruosen Xie
- Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Department of Material Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA
| | | | - Yitao Huang
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA.; The Biomedical Sciences Graduate Program, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA
| | - K Craig Kent
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA..
| | - Lian-Wang Guo
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA..
| | - Shaoqin Gong
- Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Department of Material Science and Engineering, University of Wisconsin-Madison, Madison, WI, 53715, USA.; Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53715, USA..
| | - Bowen Wang
- Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA, 22908, USA..
| |
Collapse
|
3
|
Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis. Eur J Clin Pharmacol 2021; 77:1825-1834. [PMID: 34218304 DOI: 10.1007/s00228-021-03181-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 06/24/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE Investigating the efficacy and safety of rupatadine (RUP) versus montelukast (MON) as adjuvant therapy for patients with rheumatoid arthritis (RA). METHODS From December 2018 to December 2019, 75 patients with active RA were enrolled in this randomized double-blind placebo-controlled study. The patients were randomized into three groups (n = 25 in each group); methotrexate (MTX) group which received MTX 15-25 mg/week plus placebo tablet once daily; MTX/RUP group which received MTX plus RUP 10 mg once daily; and MTX/MON group which received MTX plus MON 10 mg once daily. The treatment duration was 3 months. At baseline and 3 months after treatment, blood samples were collected for the biochemical analysis of high-sensitivity C-reactive protein (hs-CRP), interleukins 8 and 17 (IL-8, IL-17), E-selectin, and clusterin (CLU) levels. Clinical and functional assessments using Disease Activity Score-CRP (DAS28-CRP) and Multidimensional Health Assessment Questionnaire (MDHAQ) were performed. RESULTS Both RUP and MON produced clinical and functional improvements which were translated by significant improvements in DAS28-CRP score and MDHAQ. Rupatadine significantly reduced all measured parameters (P < 0.05) except for IL-17 and CLU. Montelukast significantly decreased all measured variables (P < 0.05) except for E-selectin. Interleukin-8 was positively correlated with IL-17 and CLU, while hs-CRP was positively correlated with E-selectin and body mass index (BMI). Both drugs were well tolerated; somnolence was the common side effect for RUP. No neuropsychiatric events were reported with MON. CONCLUSION Rupatadine or montelukast may serve as a potential adjuvant therapy for patients with rheumatoid arthritis secondary to the preliminary evidence of efficacy and safety. ClinicalTrials.gov identifier NCT03770923, December 10, 2018.
Collapse
|
4
|
Kugler S, Ossowicz P, Malarczyk-Matusiak K, Wierzbicka E. Advances in Rosin-Based Chemicals: The Latest Recipes, Applications and Future Trends. Molecules 2019; 24:E1651. [PMID: 31035500 PMCID: PMC6539233 DOI: 10.3390/molecules24091651] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Revised: 04/19/2019] [Accepted: 04/23/2019] [Indexed: 01/18/2023] Open
Abstract
A comprehensive review of the publications about rosin-based chemicals has been compiled. Rosin, or colophony, is a natural, abundant, cheap and non-toxic raw material which can be easily modified to obtain numerous useful products, which makes it an excellent subject of innovative research, attracting growing interest in recent years. The last extensive review in this research area was published in 2008, so the current article contains the most promising, repeatable achievements in synthesis of rosin-derived chemicals, published in scientific literature from 2008 to 2018. The first part of the review includes low/medium molecule weight compounds: Especially intermediates, resins, monomers, curing agents, surfactants, medications and biocides. The second part is about macromolecules: mainly elastomers, polymers for biomedical applications, coatings, adhesives, surfactants, sorbents, organosilicons and polysaccharides. In conclusion, a critical evaluation of the publications in terms of data completeness has been carried out with an indication of the most promising directions of rosin-based chemicals development.
Collapse
Affiliation(s)
- Szymon Kugler
- Faculty of Chemical Engineering, West Pomeranian University of Technology in Szczecin, Pulaskiego 10, 70-322 Szczecin, Poland.
| | - Paula Ossowicz
- Faculty of Chemical Engineering, West Pomeranian University of Technology in Szczecin, Pulaskiego 10, 70-322 Szczecin, Poland.
| | - Kornelia Malarczyk-Matusiak
- Faculty of Chemical Engineering, West Pomeranian University of Technology in Szczecin, Pulaskiego 10, 70-322 Szczecin, Poland.
| | - Ewa Wierzbicka
- Industrial Chemistry Research Institute, Rydygiera 8, 01-793 Warsaw, Poland.
| |
Collapse
|
5
|
Rani R, Dahiya S, Dhingra D, Dilbaghi N, Kim KH, Kumar S. Improvement of antihyperglycemic activity of nano-thymoquinone in rat model of type-2 diabetes. Chem Biol Interact 2018; 295:119-132. [PMID: 29421519 DOI: 10.1016/j.cbi.2018.02.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2017] [Revised: 01/20/2018] [Accepted: 02/02/2018] [Indexed: 12/12/2022]
Abstract
Thymoquinone is a bioactive constituent of Nigella sativa seeds. It has been reported to possess antihyperglycemic effect in rats. However, the effect of nanoformulation (NF) of thymoquinone has not been reported in literature. So, the present study was designed with the aim to investigate the effect of nanoformulation of thymoquinone in streptozotocin-nicotinamide induced type-2 diabetic rats and compare its effect with pure bioactive compound as well as metformin, a standard antidiabetic drug. It is the first study reporting the use of thymoquinone NF against diabetes. Polymeric nanocapsules (NCs) of thymoquinone and metformin were prepared by nanoprecipitation method using gum rosin, a biocompatible polymer. Box-Behnken statistical analysis tool was used for the optimization of polymer and other excipients. The NCs were then characterized with respect to particle size, stability, morphology, and in vitro drug dissolution profiles. Furthermore, thymoquinone (20, 40 & 80 mg/kg), metformin (150 mg/kg) and their nanoformulations (20, 40 & 80 mg/kg for thymoquinone and 80 mg/kg for metformin) per se were administered for 21 successive days to type-2 diabetic rats. Body weight and blood glucose levels were measured every week for 3 weeks. Serum lipid profile and glycosylated hemoglobin were estimated on 22nd day. The nanocapsules were stable, spherical in shape and size was less than 100 nm. Thymoquinone-and metformin-loaded NCs showed sustained release profile as compared to their pure forms. Oral administration of thymoquinone, metformin and their nanoformulations significantly decreased blood glucose level and glycated haemoglobin; and improved the lipid profile of diabetic rats as compared to diabetic control rats. Thymoquinone-loaded NCs (containing 10, 20 and 40 mg of thymoquinone) produced dose-dependent antihyperglycemic effect and this effect was comparable to thymoquinone and metformin. In conclusion, thymoquinone nanocapsules (actually containing half of the doses of thymoquinone) produced better antihyperglycemic effect in type-2 diabetic rats as compared to thymoquinone alone.
Collapse
Affiliation(s)
- Ruma Rani
- Department of Bio and NanoTechnology, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Shakti Dahiya
- Department of Bio and NanoTechnology, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Dinesh Dhingra
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Neeraj Dilbaghi
- Department of Bio and NanoTechnology, Guru Jambheshwar University of Science & Technology, Hisar 125001, India
| | - Ki-Hyun Kim
- Dept. of Civil & Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul 04763, Republic of Korea.
| | - Sandeep Kumar
- Department of Bio and NanoTechnology, Guru Jambheshwar University of Science & Technology, Hisar 125001, India.
| |
Collapse
|
6
|
Li Q, Huang X, Liu H, Shang S, Song Z, Song J. Preparation and properties of room temperature vulcanized silicone rubber based on rosin-grafted polydimethylsiloxane. RSC Adv 2018; 8:14684-14693. [PMID: 35540765 PMCID: PMC9080011 DOI: 10.1039/c7ra13672b] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Accepted: 03/31/2018] [Indexed: 12/22/2022] Open
Abstract
Rosin-grafted polydimethylsiloxane (RGSO) was prepared via ring-opening reaction of glycidyl ester of rosin acid (ER) with hydroxy-terminated amino polydimethylsiloxane (PDMS). The structure of RGSO was confirmed by 1H and 13C NMR spectroscopy. The effects of ER on relative molecular weight and rheological properties of RGSO were studied by gel permeation chromatography and rotational rheometry. Then, room temperature vulcanized (RTV) silicone rubber modified with rosin was prepared using RGSO, hydroxy-terminated PDMS, tetraethoxysilane, and organotin catalyst. The structures and properties of RTV silicone rubbers were studied by scanning electron microscopy, thermogravimetric analysis, a universal testing machine and dynamic mechanical analysis. The rosin-modified silicone rubber showed remarkably improved thermal and mechanical properties. Temperatures corresponding to 10% weight loss and maximum rate of weight loss increased by 66 °C and 177 °C, respectively. Moreover, the tensile strength and elongation at break increased by 138% and 113%. The role of rosin structure in improvement of properties is discussed. Rosin-grafted polydimethylsiloxane (RGSO) was prepared via ring-opening reaction of glycidyl ester of rosin acid (ER) with hydroxy-terminated amino polydimethylsiloxane (PDMS).![]()
Collapse
Affiliation(s)
- Qiaoguang Li
- Institute of Chemical Industry of Forestry Products
- Chinese Academy of Forestry
- Key Laboratory of Biomass Energy and Material
- National Engineering Laboratory for Biomass Chemical Utilization
- Key and Laboratory on Forest Chemical Engineering
| | - Xujuan Huang
- Institute of Chemical Industry of Forestry Products
- Chinese Academy of Forestry
- Key Laboratory of Biomass Energy and Material
- National Engineering Laboratory for Biomass Chemical Utilization
- Key and Laboratory on Forest Chemical Engineering
| | - He Liu
- Institute of Chemical Industry of Forestry Products
- Chinese Academy of Forestry
- Key Laboratory of Biomass Energy and Material
- National Engineering Laboratory for Biomass Chemical Utilization
- Key and Laboratory on Forest Chemical Engineering
| | - Shibin Shang
- Institute of Chemical Industry of Forestry Products
- Chinese Academy of Forestry
- Key Laboratory of Biomass Energy and Material
- National Engineering Laboratory for Biomass Chemical Utilization
- Key and Laboratory on Forest Chemical Engineering
| | - Zhanqian Song
- Institute of Chemical Industry of Forestry Products
- Chinese Academy of Forestry
- Key Laboratory of Biomass Energy and Material
- National Engineering Laboratory for Biomass Chemical Utilization
- Key and Laboratory on Forest Chemical Engineering
| | - Jie Song
- Department of Chemistry and Biochemistry
- University of Michigan-Flint
- Flint
- USA
| |
Collapse
|